ULS A.I CyberSecurity Scoring
10/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Unity Lab Services in 2026.
No incidents recorded for Unity Lab Services in 2026.
No incidents recorded for Unity Lab Services in 2026.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
Latest updates, reports, and threat intel affecting the global network.
20th October 2022, New Delhi: Thermo Fisher Scientific, the world leader in serving science, has once again cemented its place among the...
Irish cybersecurity and cloud specialist Ekco has snapped up IT services provider Unity Technology Solutions for an undisclosed sum.
SAN JOSE, CA — September 24, 2020 — Clinical research, forensic and anti-doping toxicology laboratories facing the challenges of analyzing...
UnityPoint Health has reached a $2.8 million settlement with patients and employees impacted by two data breaches at the health system.
A vulnerability was identified in Anil-matcha Open-Generative-AI up to 1.0.11/2.0.0. Affected by this issue is some unknown functionality of the file /api/upload-binary of the component S3 Upload. Such manipulation of the argument x-proxy-target-url leads to unrestricted upload. The attack may be launched remotely. The name of the patch is f013270957f75e439eaf97eb2a93decb32a4543e. Applying a patch is advised to resolve this issue.
A vulnerability was determined in Anil-matcha Open-Generative-AI up to 1.0.11/2.0.0. Affected by this vulnerability is the function renderHistory of the file ImageStudio.js of the component Studio Components. This manipulation causes cross site scripting. The attack may be initiated remotely. The pull request to fix this issue awaits acceptance.
A vulnerability was found in getzep graphiti up to 0.30.2. Affected is an unknown function of the file server/graph_service/main.py of the component REST API. The manipulation results in improper authentication. The attack can be launched remotely. The pull request to fix this issue awaits acceptance.
A vulnerability has been found in itsourcecode Sales and Inventory System 1.0. This impacts an unknown function of the file /pages/inv_edit1.php. The manipulation of the argument ID leads to sql injection. The attack can be initiated remotely. The exploit has been disclosed to the public and may be used.
The mcumgr SMP settings-management group handlers settings_mgmt_read(), settings_mgmt_write(), and settings_mgmt_delete() in subsys/mgmt/mcumgr/grp/settings_mgmt/src/settings_mgmt.c allocate a key_name buffer (and, for read, a data buffer) via k_malloc() when CONFIG_MCUMGR_GRP_SETTINGS_BUFFER_TYPE_HEAP is enabled, relying on the end: label to k_free() them. When CONFIG_MCUMGR_GRP_SETTINGS_ACCESS_HOOK is also enabled and the application access hook rejects a request by returning status MGMT_CB_ERROR_RC, the handler executed return ret_rc; directly, bypassing end: and leaking the heap allocation on every rejected request. The settings handlers are reachable over the unauthenticated SMP transport (Bluetooth LE, UART, or UDP, depending on product configuration). The access hook is the mechanism applications use to deny unauthorized settings access, and MGMT_CB_ERROR_RC is a common rejection style, so an attacker who can send settings read/write/delete commands that the hook rejects triggers a heap leak on each attempt. Because the leaked memory is never reclaimed until reboot, a sustained stream of rejected requests monotonically exhausts the kernel heap until k_malloc() fails, denying mcumgr service and impacting any other heap consumer on the device — a denial of service. The impact is availability-only; there is no memory corruption or information disclosure. Only configurations that select the heap buffer type, enable the access hook, and register a hook that returns MGMT_CB_ERROR_RC are affected (the default stack buffer type cannot leak).
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.